Skip to main content

Haemato-oncology · London

Bispecific antibody therapy, private in London.

Off-the-shelf T-cell engagers for relapsed myeloma, lymphoma and uveal melanoma. Delivered by a consultant haemato-oncologist in a JACIE-equivalent centre, with a full cytokine release syndrome pathway from day one.

A stethoscope on a clinical desk

What they are

Two arms, one job: drag T cells onto tumour cells.

Bispecific antibodies are engineered proteins that bind two different targets at once. In cancer they almost always bind CD3 on a T cell with one arm, and a tumour antigen with the other, so the patient's own T cells are pulled directly onto the malignant cell and instructed to kill it.

  • Two-armed antibody

    Unlike a standard monoclonal antibody, which binds one target, a bispecific has two different antigen-binding sites and behaves like a physical bridge between two cells.

  • T-cell engagers (TCE)

    The dominant class in oncology. One arm binds CD3 on the T cell. The other binds BCMA, GPRC5D, CD20, CD19 or gp100 on the tumour cell.

  • BiTE, DuoBody, TandAb

    BiTE (Bispecific T-cell Engager) is one construct format, of which blinatumomab is the archetype. Newer bispecifics use full IgG-like backbones for a longer half-life and easier dosing.

    • Indicative cost per cycle

    What a private bispecific antibody costs in London.

    Indicative ranges across UK units.

    In short

    Typical annual on-treatment cost: £120,000 to £220,000, depending on agent, dose schedule and duration.

    Item Indicative range
    Multidisciplinary review and treatment plan £450-£850
    Baseline work-up (echo, virology, imaging, marrow) £2,400-£4,800
    Teclistamab (Tecvayli), monthly on-treatment cost £11,500-£14,000
    Talquetamab (Talvey), monthly on-treatment cost £11,000-£13,500
    Glofitamab (Columvi), fixed 12-cycle course £8,500-£12,000
    Tebentafusp (Kimmtrak), weekly for uveal melanoma £9,500-£12,500
    Cycle-one inpatient admission for step-up dosing £6,500-£12,000

    Drug cost is the dominant component. Facility fees, cycle-one admission, tocilizumab and monthly IVIG add materially to the total.

    Where treatment is given

    A small number of London centres deliver bispecifics privately.

    Bispecific antibody therapy is offered in JACIE-accredited or equivalent cell therapy centres with a dedicated cytokine release syndrome pathway. Introductions are made privately, once we understand your case.

    • King's College Hospital Private

      Established myeloma and lymphoma cellular therapy programme in south London.

    • University College London Hospitals Private

      Comprehensive haemato-oncology and cell therapy service on Euston Road.

    • The Royal Marsden Private

      Specialist cancer centre with strong bispecific and CAR-T experience in Chelsea and Sutton.

    • The Christie Private Care

      Manchester-based specialist cancer centre for patients unable to travel to London.

    • HCA London Bridge Hospital

      HCA haemato-oncology suite with links to cellular therapy partner units.

    Bispecifics vs CAR-T

    Off-the-shelf, immediate, weekly. Or one-time, engineered, unique.

    Both work through T cells. The difference is availability, delivery and durability of response, which is what drives the choice for a given patient.

    Bispecific antibodies

    • Off-the-shelf, available in days.
    • Weekly or fortnightly dosing (some fixed duration).
    • Multiple licensed agents per indication.
    • Retreatment and sequencing possible.
    • Lower rates of higher-grade CRS and ICANS than CAR-T.

    CAR-T cell therapy

    • One-time engineered infusion of autologous T cells.
    • Apheresis, manufacturing and 3 to 6 week wait.
    • Usually one licensed product per indication.
    • Deep, durable remissions in a subset of patients.
    • Higher rates of significant CRS and ICANS.

    Response rates

    What the pivotal trials actually show.

    Rounded figures from the pivotal trials, in patients who had already exhausted standard options. Your own likely response depends on prior lines, disease burden and cytogenetics.

    • Teclistamab in myeloma

      Overall response rate around 63% after four or more prior lines (MajesTEC-1). Median duration of response around 22 months in responders.

    • Talquetamab in myeloma

      Overall response rate around 74% at the recommended weekly dose (MonumenTAL-1), including in patients previously treated with a BCMA-directed therapy.

    • Elranatamab in myeloma

      Overall response rate around 61% in triple-class exposed patients (MagnetisMM-3), with a similar tolerability profile to teclistamab.

    • Glofitamab in DLBCL

      Overall response rate around 52% (complete response 39%) in relapsed / refractory DLBCL after two or more prior lines, including post-CAR-T (NP30179).

    • Epcoritamab in DLBCL

      Overall response rate around 63% (complete response 39%) in DLBCL after two prior lines (EPCORE NHL-1).

    • Tebentafusp in uveal melanoma

      The first agent to show an overall survival benefit in metastatic uveal melanoma, roughly 22 vs 16 months versus investigator choice (IMCgp100-202).

    Licensed indications, UK 2025

    Who bispecifics are for, and who they are not for.

    Myeloma, lymphoma and uveal melanoma cover almost every UK bispecific antibody licence in 2025. B-ALL is treated with blinatumomab in cellular therapy centres.

    • Relapsed / refractory multiple myeloma

      Teclistamab (Tecvayli), talquetamab (Talvey) or elranatamab (Elrexfio) after three or more prior lines including a PI, IMiD and anti-CD38.

    • Diffuse large B-cell lymphoma post-CAR-T

      Glofitamab (Columvi) or epcoritamab (Epkinly) for DLBCL that has progressed after CAR-T or when CAR-T is not an option.

    • Follicular lymphoma, third line and beyond

      Mosunetuzumab (Lunsumio), an off-the-shelf CD20xCD3 bispecific, as a fixed-duration outpatient course for relapsed FL.

    • Metastatic uveal melanoma, HLA-A*02:01 positive

      Tebentafusp (Kimmtrak) gp100xCD3, the first agent to improve overall survival in metastatic uveal melanoma.

    • B-cell acute lymphoblastic leukaemia

      Blinatumomab (Blincyto) CD19xCD3, in MRD-positive or relapsed B-ALL as a bridge to transplant or CAR-T.

    • Bridge before or after CAR-T cell therapy

      Bispecifics can hold disease while CAR-T cells are manufactured, or salvage a patient whose CAR-T has failed.

    • Patients unfit or unable to travel for CAR-T

      Off-the-shelf availability and weekly outpatient dosing suit patients who cannot manage a CAR-T pathway or apheresis logistics.

    • Red flag: active infection or severe cytopenias

      Uncontrolled infection, neutrophils under 1.0 or platelets under 50 usually mean deferring treatment. We are honest before you commit.

    The agents

    Eight bispecifics, four disease groups, one framework.

    What each licensed agent actually is, its target, the schedule and how it is chosen in practice.

    • Teclistamab (Tecvayli), BCMAxCD3

      The first BCMA bispecific licensed for relapsed myeloma. Weekly subcutaneous injection after a 3-dose inpatient step-up. Overall response rate around 63% after four prior lines.

    • Talquetamab (Talvey), GPRC5DxCD3

      A non-BCMA target for patients who have already failed BCMA-directed therapy. Skin, nail and taste side effects are distinctive and manageable with dose adjustment.

    • Elranatamab (Elrexfio), BCMAxCD3

      A second BCMA bispecific with a comparable response profile to teclistamab. Useful when supply or scheduling favours one over the other.

    • Glofitamab (Columvi), CD20xCD3

      Fixed 12-cycle course for relapsed DLBCL, with obinutuzumab pre-treatment to blunt cytokine release syndrome. Off-the-shelf and does not need apheresis.

    • Epcoritamab (Epkinly), CD20xCD3

      Subcutaneous CD20xCD3 for DLBCL and follicular lymphoma. Continuous weekly, then fortnightly, then monthly dosing until progression.

    • Mosunetuzumab (Lunsumio), CD20xCD3

      IV, fixed-duration course of 8 cycles for relapsed follicular lymphoma. Lower rates of higher-grade cytokine release syndrome than the other CD20xCD3 agents.

    • Tebentafusp (Kimmtrak), gp100xCD3

      An immunocytokine-style TCR bispecific for HLA-A*02:01 positive metastatic uveal melanoma. Weekly IV infusion in a monitored day unit.

    • Blinatumomab (Blincyto), CD19xCD3

      A first-generation BiTE for B-ALL, delivered as a 28-day continuous IV infusion via a portable pump. Requires close inpatient supervision at initiation.

    Safety and cytokine release syndrome

    What to expect, honestly.

    Cytokine release syndrome is the defining side effect of any T-cell engager. With modern step-up dosing and premedication, most CRS is mild and manageable, but the safety pathway is built around it from day one.

    • Cytokine release syndrome (CRS)

      Most patients get some CRS in cycle one, usually grade 1 or 2 (fever, tachycardia, mild hypotension). Managed with tocilizumab and dexamethasone. Higher-grade CRS is uncommon after step-up dosing.

    • Immune effector cell neurotoxicity (ICANS)

      Confusion, tremor or dysphasia within the first cycle. Uncommon with bispecifics compared with CAR-T but taken seriously, with daily ICE score checks on the ward.

    • Infection risk and hypogammaglobulinaemia

      B-cell and plasma-cell depletion leaves you at risk of bacterial, viral and PJP infections. Monthly IVIG, aciclovir and co-trimoxazole prophylaxis are standard.

    • Cytopenias

      Neutropenia, anaemia and thrombocytopenia are common in the first three cycles. G-CSF, transfusions and dose delays are used to keep you safe.

    • Skin, nail and taste changes (talquetamab)

      GPRC5D is expressed on skin and nail keratinocytes and taste buds. Rash, dry mouth, weight loss and dysgeusia can develop, usually manageable with dose interval adjustment.

    • Injection site or infusion reactions

      Subcutaneous injections can cause local redness. IV infusions can cause fevers and rigors, especially in the first cycles, managed with premedication.

    • Hospital admission for step-up dosing

      The first two or three doses are given as an inpatient over 3 to 7 nights so that CRS and ICANS can be watched for and treated early.

    • Long-term monitoring

      Monthly bloods, imaging every 3 months and marrow or PET at response milestones. Immunoglobulin replacement continues as long as levels stay low.

    • Red flags between visits

      A fever over 38, sudden confusion or new severe headache, breathlessness, or a rash with mucosal involvement means calling the unit or attending A&E the same day.

    Reading your treatment summary

    Your bispecific plan in four parts. Read the last one first.

    Whichever agent is chosen, the summary the consultant sends you keeps to the same shape.

    A UK haemato-oncologist reviewing a bispecific antibody treatment plan

    A quiet reminder

    Haemato-oncology language is precise and can read coldly. Ask your care team to explain anything that is unclear.

    Ask your care team to explain anything that is unclear.

    1. 01 Header

      Diagnosis, prior lines and molecular profile

      What tumour, how many prior lines, and any BCMA, CD20, GPRC5D, HLA-A*02:01 or FISH data that drove the choice of bispecific.

    2. 02 Regimen

      Agent, step-up schedule and cycle plan

      Which bispecific, the step-up dose schedule for cycle one, dose escalations, and the planned duration (fixed course versus continuous until progression).

    3. 03 Findings

      CRS, ICANS and toxicity summary

      Grades of CRS, tocilizumab use, any ICANS, cytopenias and infections. The endpoint that matters here is safety across step-up dosing.

    4. 04 Impression

      Response, next dose and follow-up plan

      Read this first: response to date on PET or marrow, whether de-escalation is due, and when the next appointment, IVIG and imaging are booked.

    Recognised by major UK insurers

    BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

    Cover for bispecific antibody therapy varies by insurer, agent and indication.

    Frequently asked

    Everything we get asked about bispecifics.

    Quick answers on outpatient care, insurance, CRS, sequencing with CAR-T, duration and MDT review.

    • Is bispecific antibody therapy outpatient or inpatient?

      Cycle one, including the step-up dosing, is given as an inpatient over 3 to 7 nights so that cytokine release syndrome and neurotoxicity can be watched for and treated early. From cycle two onwards, most bispecifics move to outpatient subcutaneous or short IV dosing, weekly at first and then de-escalating to fortnightly or monthly.

    • Will my private health insurance cover a bispecific antibody?

      Cover varies. Most UK insurers will fund a bispecific when it holds an MHRA licence for your indication and when NICE or a specific policy supports it. Teclistamab, glofitamab, mosunetuzumab and tebentafusp are the ones most commonly reimbursed.

    • What is the risk of cytokine release syndrome?

      Most patients get some CRS in cycle one, but it is usually grade 1 or 2 (fever and tachycardia, sometimes mild hypotension). Higher-grade CRS is uncommon with modern step-up dosing and premedication. Tocilizumab and dexamethasone are given at the first sign of significant CRS. Serious ICU-level CRS is now rare.

    • How does a bispecific fit with CAR-T cell therapy?

      Bispecifics can be used before CAR-T (to hold disease while cells are manufactured), instead of CAR-T (when apheresis, travel or timing is not workable), or after CAR-T (as salvage when the CAR-T has failed). For DLBCL, glofitamab and epcoritamab have data specifically in post-CAR-T patients.

    • How long will I be on treatment?

      It depends on the agent. Glofitamab and mosunetuzumab are fixed-duration courses (12 and 8 cycles respectively). Teclistamab, talquetamab, elranatamab, epcoritamab and tebentafusp are given continuously until disease progression or unacceptable toxicity. In practice most patients settle onto monthly dosing once a deep response is confirmed.

    • Will my case go through a multidisciplinary team?

      Yes. This is a JACIE and BSH standard, not an optional extra.

    Related treatments and tests

    Looking for something else?